X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
humans (19) 19
melanoma (13) 13
male (12) 12
oncology (12) 12
immunotherapy (11) 11
female (10) 10
ipilimumab (9) 9
melanoma - pathology (9) 9
middle aged (9) 9
aged (8) 8
melanoma - immunology (8) 8
pembrolizumab (8) 8
safety (8) 8
abridged index medicus (7) 7
cancer (7) 7
care and treatment (7) 7
nivolumab (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
programmed cell death 1 receptor - immunology (7) 7
anti-pd-1 (6) 6
antibodies, monoclonal - administration & dosage (6) 6
melanoma - drug therapy (6) 6
antibodies, monoclonal, humanized - administration & dosage (5) 5
health aspects (5) 5
immunology (5) 5
pd-1 (5) 5
prognosis (5) 5
research (5) 5
adult (4) 4
antineoplastic agents - therapeutic use (4) 4
apoptosis (4) 4
athletes (4) 4
ctla-4 (4) 4
melanoma - therapy (4) 4
neoplasm staging (4) 4
pd-1 blockade (4) 4
responses (4) 4
retrospective studies (4) 4
secondary schools (4) 4
t-cells (4) 4
therapy (4) 4
treatment outcome (4) 4
tumors (4) 4
uveal melanoma (4) 4
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic agents (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
article (3) 3
clinical medicine (3) 3
clinical trials (3) 3
cytokines (3) 3
follow-up studies (3) 3
liver neoplasms - secondary (3) 3
metastasis (3) 3
metastatic melanoma (3) 3
motion pictures (3) 3
pharmacology & pharmacy (3) 3
randomized controlled trials as topic (3) 3
skin neoplasms - drug therapy (3) 3
skin neoplasms - pathology (3) 3
untreated melanoma (3) 3
advanced melanoma (2) 2
affordable housing (2) 2
age factors (2) 2
antibodies, monoclonal - immunology (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antigens (2) 2
antimitotic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacology (2) 2
atezolizumab (2) 2
b7-h1 antigen - immunology (2) 2
bees (2) 2
blockade (2) 2
cancer therapies (2) 2
cardiovascular-disease (2) 2
cell line, tumor (2) 2
cell lung-cancer (2) 2
china (2) 2
clinical study (2) 2
cohort studies (2) 2
college football (2) 2
cost of living (2) 2
ctla-4 antigen - immunology (2) 2
ctla-4 antigen - metabolism (2) 2
ctla-4 blockade (2) 2
dermatology (2) 2
development and progression (2) 2
diagnosis (2) 2
disease-free survival (2) 2
documentary films (2) 2
double-blind (2) 2
double-blind method (2) 2
efficacy (2) 2
football (2) 2
gene expression regulation, neoplastic - drug effects (2) 2
health (2) 2
identification (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


New Phytologist, ISSN 0028-646X, 10/2014, Volume 204, Issue 1, pp. 37 - 54
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3447 - 3452
Journal Article
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Cancer, ISSN 0008-543X, 07/2018, Volume 124, Issue 13, pp. 2693 - 2703
The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of... 
treatment | barriers | trials | challenges | outcomes | success | therapy | uveal melanoma | PROGNOSTIC IMPLICATIONS | DEPENDENT PROBE AMPLIFICATION | TUMOR DIAMETER | CHOROIDAL MELANOMA | COMPLETE RESECTION | LIVER METASTASES | UNTREATED MELANOMA | ONCOLOGY | DOUBLE-BLIND | GENE-EXPRESSION PROFILE | INTRAARTERIAL HEPATIC FOTEMUSTINE | Uveal Neoplasms - therapy | Risk Assessment - methods | Melanoma - diagnosis | Prognosis | Uvea - pathology | Ophthalmology - standards | Humans | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Mass Screening - methods | Medical Oncology - organization & administration | Patient Care Team - organization & administration | Skin Neoplasms - diagnosis | Treatment Failure | Uvea - diagnostic imaging | Antineoplastic Agents - pharmacology | Liver Neoplasms - secondary | Molecular Targeted Therapy - methods | Watchful Waiting - standards | Liver Neoplasms - prevention & control | Patient Care Team - standards | Uveal Neoplasms - pathology | Skin Neoplasms - therapy | Mass Screening - standards | Treatment Outcome | Clinical Trials as Topic | Melanoma - pathology | Randomized Controlled Trials as Topic | Liver Neoplasms - diagnosis | Chemotherapy, Adjuvant - methods | Ophthalmology - organization & administration | Progression-Free Survival | Uveal Neoplasms - mortality | Medical Oncology - standards | Uveal Neoplasms - diagnosis | Watchful Waiting - organization & administration | Melanoma - therapy | Melanoma - mortality | Practice Guidelines as Topic | Medical research | Barriers | Medical services | Melanoma | Radiation | Clinical trials | Ophthalmology | Cancer
Journal Article
Melanoma Management, ISSN 2045-0885, 05/2017, Volume 4, Issue 2, pp. 79 - 82
Despite this limitation, first-line treatment with pembrolizumab or nivolumab plus ipilimumab is widely used, with clinicians in many cases extrapolating from... 
toxicity | pembrolizumab | nivolumab | safety | uveal melanoma | immunotherapy | PD-L1 | atezolizumab | PD-1 | Inflammatory bowel disease | Hepatitis | Immunoglobulins | Medical prognosis | Immunotherapy | Melanoma | Response rates | Diarrhea | Metastasis | Mutation | Cancer therapies
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 9, pp. 1141 - 1147
Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response... 
nivolumab | EFFICACY | SAFETY | advanced melanoma | TUMOR | CANCER-IMMUNOTHERAPY | pembrolizumab | METASTATIC MELANOMA | prediction scale | ONCOLOGY | immunotherapy | ANTI-PD-1 | T-CELLS | IPILIMUMAB | Clinical Study
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2017, Volume 197, Issue 4, pp. e274 - e275
Journal Article
Immunity, ISSN 1074-7613, 02/2019, Volume 50, Issue 2, pp. 477 - 492.e8
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved... 
activation-induced cell death | IFN-γ | cancer | anti-CTLA-4 | anti-PD-1 | immunotherapy | RESPONSES | SOLID TUMORS | ANTI-CTLA-4 | IMMUNOTHERAPY | PD-1 BLOCKADE | IFN-GAMMA | COMBINED NIVOLUMAB | ACQUIRED-RESISTANCE | IMMUNOLOGY | CANCER | IPILIMUMAB | Humans | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Interferon-gamma - metabolism | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Clonal Deletion - drug effects | Neoplasms, Experimental - immunology | Antibodies, Monoclonal - immunology | Antibodies, Monoclonal - pharmacology | Mice, Inbred C57BL | CTLA-4 Antigen - metabolism | Programmed Cell Death 1 Receptor - metabolism | Drug Resistance, Neoplasm - immunology | CTLA-4 Antigen - immunology | Clonal Deletion - immunology | Mice, Knockout | Animals | Tumor Burden - drug effects | Interferon-gamma - immunology | Cell Line, Tumor | T-Lymphocytes - immunology | Neoplasms, Experimental - metabolism | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Neoplasms, Experimental - drug therapy | Interferon-gamma - pharmacology | Drug Resistance, Neoplasm - drug effects | Tumor Burden - immunology | Antigens | PD-1 protein | Melanoma | Clinical trials | Lymphocytes T | Immune status | Metastasis | Cancer therapies | Immunity | Clinical outcomes | CTLA-4 protein | Immune checkpoint | Clonal deletion | Lymphocytes | Immunotherapy | γ-Interferon | Interferon | Mutation | Tumors | Apoptosis
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3344 - 3353
Journal Article